Wer bestimmt das "Wohl" eines Heimbewohners? : Entscheidungen in Grenzfällen – Ethik-Komitees fördern Abwägungsprozesse

Das Altenpflegeheim ist für die Heimbewohner einerseits ihr Zuhause, andererseits wird es aber von vielen alten Menschen als der erzwungene Daueraufenthalt bis zum Lebensende empfunden. Dies ruft in den Beziehungen zwischen Heimbewohnern, ihren Angehörigen und den Pflegenden oftmals Spannungen hervor, die das zentrale Recht der Bewohnerinnen und Bewohner, aber auch das zentrale Anliegen der Pflegenden tangieren: die Erhaltung und Förderung der Selbstbestimmtheit des alten Menschen. Viele der betroffenen Heimbewohner sind vor allem aufgrund von Demenzerkrankungen unterschiedlicher Genese nicht mehr einwilligungsfähig. Dennoch äußern sie durch Gestik und Mimik in recht differenzierter Weise ihre Freude, ihre Vorlieben, ihre Ängste und ihren Unwillen. So zeigen sie oftmals, ob sie einer therapeutischen oder pflegerischen Maßnahme zustimmen oder sie ablehnen. Diese außerordentlich schwer zu interpretierenden Willensäußerungen sind zweifellos eine erhebliche Herausforderung, die nur in Kooperation aller Beteiligten gelöst werden kann

Development of a laser shock adhesion test for the assessment of weak adhesive bonded CFRP structures

Adhesive bondin,g bas a great poœnlial far future ligbtweight bigb-loaded structures in the a.eronautic industiy. A preœquisite for sucb an application is dtat the bond quality of the adhesive joint can be assessed in a non-destructive way. However, the use of da.ssicaJ Non•DesiiUctive Techniques (NDT) does not aUow the evaluation of the adhesion stren,gt:h of an adhesive bond yet This paper pn!sents an investigation made on weak composite bonds in on!er to develop a laser shock wave adhesion test First, the procedure to produce controlled weak bonds is desaibed. CFRP bonded samples are pn!pared in a spedfic way and characterized by ultrasonic techniques to assess the absence of any detectable defect. 1ben, for sorne of the .samples, their bond streDgth is evaluated by mechanical destructive œsts and ether .samples are loaded by v.arious intensity lasers shocks. The obtained results help to understand the behavior of the composite bonds under Jaser shock loading:. thanks to two post-mortem techrùques. 1becorrelation between the laser parameterS and the induced damage is demon.strated, The potential of the laser shock. technique to dl.saiminate different bond quallties is shawn, and the need for the œst optinùzationlsdÛ(

A study of composite material damage induced by laser shock waves

A laser shock wave technique has been used to study the damage tolerance of T800/M21 CFRP (Carbon Fiber Reinforced Polymer) composite material with different lay_ups. Different levels of damage have been created according to various laser irradiation conditions. Several characterization methods such as Optical Microscopy, X-ray Radiography, or Interferometric Confocal Microscopy have been used to quantify these defects. The nature of the defects induced by the shock wave propagation has been studied. The sensitivity of the composite material damage to the shock conditions has been shown and quantified. Moreover, the experimental results gathered with each technique have been compared to each other and it leads to a better understanding of the CFRP behavior under high dynamic loading. These original results have enabled the definition of a specific damage criterion for CFRP under dynamic loading

Ethical and legal points of view in parenteral nutrition – Guidelines on Parenteral Nutrition, Chapter 12

Adequate nutrition is a part of medical treatment and is influenced by ethical and legal considerations. Patients, who cannot be sufficiently fed via the gastrointestinal tract, have the fundamental right to receive PN (parenteral nutrition) even so patients who are unable to give their consent. General objectives in nutrition support are to supply adequate nutrition with regards to the prevention of malnutrition and its consequences (increased morbidity and mortality), and thereby promoting improved outcome and/or quality of life for the patient considering always the patient’s needs and wishes. The requests of the patient to renounce PN should be respected where a signed living will is helpful. During the course of a terminal illness the nutrition has to be adapted individually according to the needs and wishes of a patient in the corresponding phase. Capability of consent should be checked in each individual case and for each measure on an individual basis. Consent should only be accepted if the patient is capable of recognizing the nature, meaning and importance of the intervention as well as the consequences of relinquishment of such an intervention, and is capable to make a self-determined decision. If the patient is not capable of consenting, the patient’s living will is the most important document when determining their assumed will and legally binding. Otherwise a guardian appointed by the patient, or the representative appointed by the court (if the patient has made no provisions) can make the decision

Das Verbot der pränatalen Diagnostik spätmanifestierender Erkrankungen im deutschen Gendiagnostikgesetz - eine Diskussion medizinischer und rechtlicher Aspekte und deren Implikation für die medizinethische Diskussion

Zusammenfassung: Am 1. Februar 2010 ist das Gendiagnostikgesetz (GenDG) in Kraft getreten. Die Debatte um einige Regelungsbereiche, wie beispielsweise das Neugeborenenscreening, reißt nicht ab. Ein Aspekt des Gesetzes ist im Rahmen der Debatte um die Präimplantationsdiagnostik (PID) in Deutschland unter neuen Vorzeichen zu diskutieren: Das - international bislang einzigartige - Verbot der pränatalen Diagnostik so genannter spätmanifestierender Erkrankungen, die erst nach der Vollendung des 18. Lebensjahres ausbrechen. In diesem Beitrag möchten wir Hinweise zur differenzierten Diskussion dieser in §15(2) GenDG bestimmten Verbotsnorm liefern. Obgleich Argumente, insbesondere das Recht auf Nichtwissen des geborenen Kindes, für ein solches Verbot sprechen, kommen wir aufgrund der medizinischen Sachlage und nach einer Analyse der Pro- und Kontraargumente aus ethischer und rechtlicher Sicht zu dem Schluss, dass ein generelles Verbot der pränatalen Diagnostik spätmanifestierender Erkrankungen im Sinne der Zielsetzung womöglich insuffizient ist sowie in der Begründung Inkonsistenzen zum bereits bestehenden Regelwerk aufweist, und lenken daher den Blick auf unter Umständen bessere Alternativen

Percutaneous Endovascular Treatment of Innominate Artery Lesions

AbstractPurposeTo assess primary success and safety of percutaneous transluminal angioplasty and/or stenting of innominate artery lesions and to compare its 30-day stroke/mortality level with the literature data.MethodsA total of 72 patients (77 stenoses, five recurrent, 58 symptomatic and 39 female) with seven innominate vessel occlusions, nine subocclusive lesions and 61 significant (>60%) stenoses of innominate artery treated between 2000 and 2009 were retrospectively reviewed. With the exception of seven, all procedures were performed using a transfemoral approach. A stent was implanted in 49 (63.6%) cases. Follow-up included neurological examination, carotid duplex scan and office/telephone interview.ResultsPrimary technical success was 93.5% (72/77). There was neither periprocedural (<48h) death, nor major neurological complication. Minor periprocedural neurological complications consisted of 2/72 (2.6%) ipsilateral TIAs. Access site complications included 4 (5.2%) access site bleedings. Follow-up was achieved in 65/72 (90.3%) of all patients and 68 (88.3%) of all procedures for a mean of 42.3 months and revealed neither major neurological complication, nor additional TIA.The cumulative primary patency rate was 100% at 12 months, 98±1.6% at 24 months, and 69.9±8.5% at 96 months. The cumulative secondary patency rate was 100% at 12 and at 24 months, and 81.5±7.7% at 96 months. Log-rank test showed no significant difference (p=0.79) in primary cumulative patencies between PTA alone (n=28) or PTA/stent (n=49).ConclusionTransfemoral PTA with or without stent appears to be a safe treatment option for innominate artery lesions

Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia

Background: Antipsychotic medication can cause tardive dyskinesia (TD) – late-onset, involuntary, repetitive movements, often involving the face and tongue. TD occurs in > 20% of adults taking antipsychotic medication (first-generation antipsychotics for > 3 months), with this proportion increasing by 5% per year among those who continue to use these drugs. The incidence of TD among those taking newer antipsychotics is not different from the rate in people who have used older-generation drugs in moderate doses. Studies of TD have previously been found to be limited, with no treatment approach shown to be effective. Objectives: To summarise the clinical effectiveness and safety of treatments for TD by updating past Cochrane reviews with new evidence and improved methods; to undertake public consultation to gauge the importance of the topic for people living with TD/the risk of TD; and to make available all data from relevant trials. Data sources: All relevant randomised controlled trials (RCTs) and observational studies. Review methods: Cochrane review methods, network meta-analysis (NMA). Design: Systematic reviews, patient and public involvement consultation and NMA. Setting: Any setting, inpatient or outpatient. Participants: For systematic reviews, adults with TD who have been taking a stable antipsychotic drug dose for > 3 months. Interventions: Any, with emphasis on those relevant to UK NHS practice. Main outcome measures: Any measure of TD, global assessments and adverse effects/events. Results: We included 112 studies (nine Cochrane reviews). Overall, risk of bias showed little sign of improvement over two decades. Taking the outcome of ‘TD symptoms improved to a clinically important extent’, we identified two trials investigating reduction of antipsychotic dose [n = 17, risk ratio (RR) 0.42, 95% confidence interval (CI) 0.17 to 1.04; very low quality]. Switching was investigated twice in trials that could not be combined (switching to risperidone vs. antipsychotic withdrawal: one RCT, n = 42, RR 0.45, 95% CI 0.23 to 0.89; low quality; switching to quetiapine vs. haloperidol: one RCT, n = 45, RR 0.80, 95% CI 0.52 to 1.22; low quality). In addition to RCTs, six observational studies compared antipsychotic discontinuation with decreased or increased dosage, and there was no clear evidence that any of these strategies had a beneficial effect on TD symptoms (very low-quality evidence). We evaluated the addition to standard antipsychotic care of several treatments, but not anticholinergic treatments, for which we identified no trials. We found no clear effect of the addition of either benzodiazepines (two RCTs, n = 32, RR 1.12, 95% CI 0.6 to 2.09; very low quality) or vitamin E (six RCTs, n = 264, RR 0.95, 95% CI 0.89 to 1.01; low quality). Buspirone as an adjunctive treatment did have some effect in one small study (n = 42, RR 0.53, 95% CI 0.33 to 0.84; low quality), as did hypnosis and relaxation (one RCT, n = 15, RR 0.45, 95% CI 0.21 to 0.94; very low quality). We identified no studies focusing on TD in people with dementia. The NMA model found indirect estimates to be imprecise and failed to produce useful summaries on relative effects of interventions or interpretable results for decision-making. Consultation with people with/at risk of TD highlighted that management of TD remains a concern, and found that people are deeply disappointed at the length of time it has taken researchers to address the issue. Limitations: Most studies remain small and poorly reported. Conclusions: Clinicians, policy-makers and people with/at risk of TD are little better informed than they were decades ago. Underpowered trials of limited quality repeatedly fail to provide answers. Future work: TD reviews have data from current trials extracted, tabulated and traceable to source. The NMA highlights one context in which support for this technique is ill advised. All relevant trials, even if not primarily addressing the issue of TD, should report appropriate binary outcomes on groups of people with this problem. Randomised trials of treatments for people with established TD are indicated. These should be large (> 800 participants), necessitating accrual through accurate local/national registers, including an intervention with acceptable treatments and recording outcomes used in clinical practice. Study registration: This study is registered as PROSPERO CRD4201502045. Funding: The National Institute for Health Research Health Technology Assessment programme